A Delay Differential Model for Pandemic Influenza with Antiviral Treatment

被引:0
|
作者
Murray E. Alexander
Seyed M. Moghadas
Gergely Röst
Jianhong Wu
机构
[1] National Research Council Canada,Institute for Biodiagnostics
[2] The University of Winnipeg,Department of Mathematics and Statistics
[3] The University of Winnipeg,Department of Physics
[4] University of Szeged,Analysis and Stochastics Research Group, Hungarian Academy of Sciences, Bolyai Institute
[5] York University,Centre for Disease Modelling, Department of Mathematics and Statistics
来源
Bulletin of Mathematical Biology | 2008年 / 70卷
关键词
Influenza pandemic; Antiviral treatment; Delay equations; Epidemic model;
D O I
暂无
中图分类号
学科分类号
摘要
The use of antiviral drugs has been recognized as the primary public health strategy for mitigating the severity of a new influenza pandemic strain. However, the success of this strategy requires the prompt onset of therapy within 48 hours of the appearance of clinical symptoms. This requirement may be captured by a compartmental model that monitors the density of infected individuals in terms of the time elapsed since the onset of symptoms. We show that such a model can be expressed by a system of delay differential equations with both discrete and distributed delays. The model is analyzed to derive the criterion for disease control based on two critical factors: (i) the profile of treatment rate; and (ii) the level of treatment as a function of time lag in commencing therapy. Numerical results are also obtained to illustrate the feasible region of disease control. Our findings show that due to uncertainty in the attack rate of a pandemic strain, initiating therapy immediately upon diagnosis can significantly increase the likelihood of disease control and substantially reduce the required community-level of treatment. This suggests that reliable diagnostic methods for influenza cases should be rapidly implemented within an antiviral treatment strategy.
引用
收藏
页码:382 / 397
页数:15
相关论文
共 50 条
  • [41] Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico
    Gerardo Chowell
    Cécile Viboud
    Lone Simonsen
    Mark A Miller
    Santiago Echevarría-Zuno
    Margot González-León
    Víctor H Borja Aburto
    BMC Infectious Diseases, 12
  • [42] Antiviral Medications in Seasonal and Pandemic Influenza A Systematic Review
    Lehnert, Regine
    Pletz, Mathias
    Reuss, Annicka
    Schaberg, Tom
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2016, 113 (47): : 799 - +
  • [43] Effective use of a Limited Antiviral Stockpile for Pandemic Influenza
    Nimalan Arinaminpathy
    J. Savulescu
    Angela R. Mclean
    Journal of Bioethical Inquiry, 2009, 6 : 171 - 179
  • [44] Effective use of a Limited Antiviral Stockpile for Pandemic Influenza
    Arinaminpathy, Nimalan
    Savulescu, J.
    Mclean, Angela R.
    JOURNAL OF BIOETHICAL INQUIRY, 2009, 6 (02) : 171 - 179
  • [45] Estimation of optimal antiviral stockpile for a novel influenza pandemic
    Kim, Soyoung
    Bin Seo, Yu
    Lee, Jacob
    Kim, Yang Soo
    Jung, Eunok
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (07) : 720 - 725
  • [46] Use of antiviral agents and other measures in an influenza pandemic
    Groeneveld, K
    van der Noordaa, J
    NETHERLANDS JOURNAL OF MEDICINE, 2005, 63 (09): : 339 - 343
  • [47] Pandemic Influenza: Antiviral Preparedness and Health Care Workers
    Schneider, Ruth B.
    Benitez, John G.
    D'Angelo, Anne
    Tyo, Kathee
    DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2010, 4 (01) : 55 - 61
  • [48] Can Antiviral Drugs Contain Pandemic Influenza Transmission?
    Becker, Niels G.
    Wang, Dingcheng
    PLOS ONE, 2011, 6 (03):
  • [49] Antiviral Drugs for the Treatment and Prevention of Influenza
    Rubaiyea Farrukee
    Aeron C. Hurt
    Current Treatment Options in Infectious Diseases, 2017, 9 (3) : 318 - 332
  • [50] Investigational antiviral therapies for the treatment of influenza
    Yang, Jie
    Huang, Yingna
    Liu, Shuwen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (05) : 481 - 488